Standard Therapy in Cardiac Amyloidosis: What is Known, What is "Gray".
Heart Fail Clin
; 20(3): 325-331, 2024 Jul.
Article
em En
| MEDLINE
| ID: mdl-38844303
ABSTRACT
Amyloidosis is a systemic disease due to the accumulation of misfolded amyloid fibrils that damage the heart and worsen the prognosis. Heart failure (HF), a condition frequently linked with an advanced stage of this disease, is the most prevalent clinical manifestation that leads to its diagnosis. However, due to the growing awareness of the occurrence of cardiac amyloidosis (CA), it is now possible to perform an early diagnosis and have a positive impact on its natural course. This study aims to highlight the most compelling issues concerning patients' clinical management with HF and CA.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Insuficiência Cardíaca
/
Amiloidose
/
Cardiomiopatias
Limite:
Humans
Idioma:
En
Revista:
Heart Fail Clin
Ano de publicação:
2024
Tipo de documento:
Article